Canada Markets closed
  • S&P/TSX

    17,094.53
    +75.43 (+0.44%)
     
  • S&P 500

    3,577.59
    +20.05 (+0.56%)
     
  • DOW

    29,591.27
    +327.79 (+1.12%)
     
  • CAD/USD

    0.7645
    +0.0007 (+0.0940%)
     
  • CRUDE OIL

    42.84
    +0.42 (+0.99%)
     
  • BTC-CAD

    24,062.29
    -85.56 (-0.35%)
     
  • CMC Crypto 200

    365.47
    +4.04 (+1.12%)
     
  • GOLD FUTURES

    1,835.20
    -37.20 (-2.02%)
     
  • RUSSELL 2000

    1,818.30
    +32.96 (+1.85%)
     
  • 10-Yr Bond

    0.8570
    +0.0280 (+3.38%)
     
  • NASDAQ futures

    11,918.50
    +12.75 (+0.11%)
     
  • VOLATILITY

    22.66
    -1.04 (-4.39%)
     
  • FTSE

    6,333.84
    -17.61 (-0.28%)
     
  • NIKKEI 225

    25,527.37
    -106.93 (-0.42%)
     
  • CAD/EUR

    0.6453
    +0.0016 (+0.25%)
     

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

Newsfile Corp.
·1 min read

Los Angeles, California--(Newsfile Corp. - October 30, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Intercept Pharmaceuticals, Inc. ("Intercept" or "the Company") (NASDAQ: ICPT) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. News outlets reported on October 8, 2020, that Intercept is "facing an investigation from the U.S. Food and Drug Administration over the potential risk of liver injury in patients taking Ocaliva, [Intercept's] treatment for primary biliary cholangitis, a rare, chronic liver disease." Based on this news, shares of Intercept fell by 8% on the same day.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.

310-301-3335
info@schallfirm.com
www.schallfirm.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/67198